Opus Genetics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRD research report →
Range $8 – $20
Price Chart
About the company
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders.
- CEO
- George Magrath
- IPO
- 2015
- Employees
- 28
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on IRD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $363.70M
- P/E
- -3.47
- Fwd P/E
- 10.80
- PEG
- 0.08
- P/S
- 36.90
- P/B
- -32.39
- EV/EBITDA
- -2.95
- Div Yield
- 0.00%
- Gross Margin
- 99.87%
- Op Margin
- -513.47%
- Net Margin
- -1091.82%
- ROE
- 1147.63%
- ROIC
- -59.29%
Latest fiscal year · YoY change
- Revenue
- $14.20M+29.1%
- Gross Profit
- $14.20M+29.1%
- Op Income
- $-38,599,000
- Net Income
- $-49,591,000+13.8%
- EPS
- $-0.80+62.8%
- OCF Growth
- -37.8%
- FCF Growth
- -37.8%
- 52W High
- $7.07
- 52W Low
- $1.70
- 50D MA
- $4.36
- 200D MA
- $4.00
- Beta
- 0.58
- RSI (14)
- 43
- Avg Volume
- 2.33M
No earnings-call transcripts are available for IRD yet.
- Free Float
- 42.4%
- Shares Outstanding
- 82.57M
- Float Shares
- 34.98M
Buy/sell ratio 0.22. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 82 ETFs
Biggest fund positions in IRD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Foundation Fighting Blindness Retinal Degeneration Fund | sell | 556,000 |
| Sep 9, 26 | Magrath George | other | 392,157 |
| Sep 9, 26 | Magrath George | other | 75,541 |
| Sep 9, 26 | Magrath George | other | 392,157 |
| Sep 8, 26 | Gallagher Cam | other | 784,314 |
| Sep 8, 26 | Gallagher Cam | other | 784,314 |
| Sep 3, 26 | Gagnon Robert E. | sell | 28,000 |
| Jul 23, 26 | YERXA BENJAMIN R | sell | 7,429 |
| Jul 23, 26 | SCHACHLE JOSEPH K | sell | 4,644 |
| Jul 23, 26 | Magrath George | sell | 9,475 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IRD coverage
Recent articles, reports, and earnings notes.
No research on IRD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRD report →Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
defenseworld.net · Oct 1
Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD
defenseworld.net · Sep 17
Opus Genetics: A Resounding Study Success Merits A Higher Valuation
seekingalpha.com · Sep 10
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
seekingalpha.com · Sep 10
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
benzinga.com · Sep 9
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
globenewswire.com · Sep 9
Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $10.69
defenseworld.net · Sep 9
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
globenewswire.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.